New to The Street announced a comprehensive media partnership with Lantern Pharma (LTRN). The collaboration includes a full-year series of national TV interviews, commercial campaigns, earned media placements, and iconic billboard exposure across New York City’s Financial District and Times Square. The partnership will also integrate non-deal roadshow coverage, bringing Lantern Pharma’s story directly to institutional and accredited investor audiences across key U.S. markets. Lantern Pharma will be featured on New to The Street’s nationally syndicated broadcasts airing on Bloomberg Television and Fox Business Network as sponsored programming, alongside coverage across the show’s digital, social, and outdoor media platforms.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN:
- Lantern Pharma presents clinical data from LP-284
- Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors
- Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment?
- Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment
- Lantern Pharma Holds Annual Stockholders Meeting
